Altekruse SF, Kosary CL, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
American Cancer Society. Cancer Facts & Figures 2011. Atlanta, Ga: American Cancer Society; 2011.
American Cancer Society. Cancer Facts & Figures 2012. Atlanta, Ga: American Cancer Society; 2012.
American Joint Committee on Cancer. Exocrine and Endocrine Pancreas. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:241−246.
Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007 Aug 15;110(4):738−744.
Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, Talamonti MS. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg. 2007 Oct;205(4):558-563.
Caprotti R, Brivio F, Fumagalli L, et al. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. Anticancer Res. 2008 May-Jun;28(3B):1951−1954.
Chen J, Li D, Killary AM, et al. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol. 2009 Feb;16(2):431−439. Epub 2008 Nov 20.
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817−1825.
Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513−5518. Epub 2009 Oct 26.
Debrin JA, Sun W, Metz JM, Furth EE. Carcinoma of the Pancreas. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008: 1595−1609.
Fjallskog ML, Janson ET, Falkmer UG, et al. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology. 2008;88(1):53−58.
Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73:485−492.
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010 Apr 20;7(4):e1000267.
Hirooka Y, Itoh A, Kawashima H, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas. 2009 Apr;38(3):e69−74.
Kulke MH, Tempero MA, Niedzwiecki D, et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20;27(33):5506−5512. Epub 2009 Oct 26.
Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008 May 1;26(13):2124−2130.
Lai G, O'Dorisio T, McDougall R, Weigall RJ. Cancer of the endocrine system. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008: 1271−1305.
Lipton A, Campbell-Baird C, Witters L, Harvey H, Ali S. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol. 2010 Apr;44(4):286−288.
Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. J Clin Oncol. 2011 Oct 3. [Epub ahead of print]
National Cancer Institute. Physician Data Query (PDQ). Pancreatic Cancer: Treatment. 8/13/2010. Accessed at http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/healthprofessional on October 21, 2011.
National Cancer Institute. Physician Data Query (PDQ). Islet cell tumors (endocrine pancreas). 10/31/2008. Accessed at http://www.cancer.gov/cancertopics/pdq/treatment/isletcell/healthprofessional on October 21, 2011.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. V.1.2012. Accessed at www.nccn.org on October 19, 2011.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine tumors. V.1.2011. Accessed at www.nccn.org on October 19, 2011.
Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8;304(10):1073−1081.
Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist. 2008;13:562−576.
Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17;297(3):267−277.
Online Mendelian Inheritance in Man, OMIM. Lynch syndrome. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), Available at: http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM. Accessed 8/25/2009.
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501−513.
Royal RE, Wolff RA, Crane CH. Pancreatic Cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008:1086−1124.
Wolff RA, Crane CH, Abbruzzese JL, Li D, Evans DB. Neoplasms of the exocrine pancreas. In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E. Cancer Medicine 7. Hamilton, Ontario: BC Decker; 2006:1331−1358.
Yang GY, Wagner TD, Fuss M, et al. Multimodality approaches for pancreatic cancer. CA Cancer J Clin. 2005;55:352−367.
Yao JC, Rindi G, Evans DB. Pancreatic endocrine tumors. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008: 1702−1721.
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514−523.
Feedback
